Ezh2 Mutation Positive Relapsed Or Refractory Follicular Lymphoma Therapeutics
1. Tazverik patent expiration
Treatment: Method of treating a lung metastasis of epithelioid sarcoma; Method of treating relapsed or refractory follicular lymphoma; Method of treating relapsed or refractory follicular lymphoma positive for a...
TAZVERIK's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9394283 | EPIZYME | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(7 years from now) | |
| US11052093 | EPIZYME | Aryl-or heteroaryl-substituted benzene compounds |
Sep, 2031
(5 years from now) | |
| US9090562 | EPIZYME | Aryl- or heteroaryl-substituted benzene compounds |
Sep, 2031
(5 years from now) | |
| US12168015 | EPIZYME | Aryl-or heteroaryl-substituted benzene compounds |
Sep, 2031
(5 years from now) | |
| US8410088 | EPIZYME | Aryl- or heteroaryl-substituted benzene compounds |
Jan, 2034
(7 years from now) | |
| US10821113 | EPIZYME | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9872862 | EPIZYME | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(7 years from now) | |
| US9522152 | EPIZYME | Aryl- or heteroaryl-substituted benzene compounds |
Apr, 2032
(6 years from now) | |
| US9889138 | EPIZYME | Method for treating cancer |
Oct, 2035
(9 years from now) | |
| US8765732 | EPIZYME | Aryl- or heteroaryl-substituted benzene compounds |
Sep, 2031
(5 years from now) | |
| US9549931 | EPIZYME | Aryl- or heteroaryl-substituted benzene compounds |
Sep, 2031
(5 years from now) | |
| US9334527 | EPIZYME | Inhibitors of human EZH2, and methods of use thereof |
Sep, 2031
(5 years from now) | |
| US9333217 | EPIZYME | Inhibitors of human EZH2, and methods of use thereof |
Sep, 2031
(5 years from now) | |
| US8691507 | EPIZYME | Inhibitors of human EZH2 and methods of use thereof |
Sep, 2031
(5 years from now) | |
| US9175331 | EPIZYME | Inhibitors of human EZH2, and methods of use thereof |
Sep, 2031
(5 years from now) | |
| US8895245 | EPIZYME | Inhibitors of human EZH2 and methods of use thereof |
Sep, 2031
(5 years from now) | |
| US9949999 | EPIZYME | Inhibitors of human EZH2, and methods of use thereof |
Sep, 2031
(5 years from now) | |
| US10369155 | EPIZYME | Method for treating cancer |
Oct, 2035
(9 years from now) | |
| US10420775 | EPIZYME | Aryl-or heteroaryl-substituted benzene compounds |
Sep, 2031
(5 years from now) | |
| US12168014 | EPIZYME | Method for treating cancer |
May, 2038
(12 years from now) | |
| US12162865 | EPIZYME | Methods of treating cancer |
Jun, 2034
(8 years from now) | |
| US12168016 | EPIZYME | Aryl-OR heteroaryl-substituted benzene compounds |
Sep, 2031
(5 years from now) | |
| US10155002 | EPIZYME | Aryl- or heteroaryl-substituted benzene compounds |
Sep, 2031
(5 years from now) | |
| US9688665 | EPIZYME | Methods of treating cancer |
Aug, 2034
(8 years from now) | |
| US9855275 | EPIZYME | Aryl-or heteroaryl-substituted benzene compounds |
Sep, 2031
(5 years from now) | |
| US10245269 | EPIZYME | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(7 years from now) | |
| US12161645 | EPIZYME | Aryl-or heteroaryl-substituted benzene compounds |
Sep, 2031
(5 years from now) | |
| US11491163 | EPIZYME | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(7 years from now) | |
| US10786511 | EPIZYME | Method for treating cancer |
Dec, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-835) | Jun 18, 2023 |
| New Indication(I-836) | Jun 18, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jan 23, 2025 |
| Orphan Drug Exclusivity(ODE-299) | Jan 23, 2027 |
| Orphan Drug Exclusivity(ODE-314) | Jun 18, 2027 |
Drugs and Companies using TAZEMETOSTAT HYDROBROMIDE ingredient
NCE-1 date: 24 January, 2024
Market Authorisation Date: 23 January, 2020
Dosage: TABLET
More Information on Dosage
TAZVERIK family patents
